AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSL LIMITED

263.910

-0.800-0.30%

Volume:333.72K

Turnover:88.01M

Market Cap:127.79B

PE:29.14

High:265.300

Open:264.000

Low:262.230

Close:264.710

Loading ...

Overview Company News Filings

CSL’s mixed half-year: plasma strength offsets vaccine weakness, bright outlook maintained

Should you buy the dip on ASX healthcare stocks CSL, Cochlear and Pro Medicus?

CSL First Half 2025 Earnings: EPS Misses Expectations

Simply Wall St.

Top brokers name 3 ASX shares to buy next week

Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results

Simply Wall St.

These ASX 200 shares could rise 20% to 40%

European Commission Approves CSL and Arcturus Therapeutics' Kostaive®, the First Self-Amplifying Mrna Covid-19 Vaccine

THOMSON REUTERS

European Commission Approves CSL and Arcturus Therapeutics’ Kostaive®, the First Self-Amplifying Mrna Covid-19 Vaccine

THOMSON REUTERS

BRIEF-European Commission Approves CSL's ANDEMBRY (Garadacimab) For The Prevention Of Recurrent Attacks Of Hereditary Angioedema (HAE)

European Commission Approves CSL's Andembry® (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (Hae)

THOMSON REUTERS

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

3 ASX growth stocks to watch as earnings hit a turning point

4 ASX 300 shares with ex-dividend dates before this week ends

Top brokers name 3 ASX shares to buy today

Flu Vaccines Proving Problematic for CSL -- Market Talk

Everything you need to know about the latest CSL dividend

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSL.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":263.91,"timestamp":1741148533109,"preClose":264.71,"halted":0,"volume":333720,"delay":0,"changeRate":-0.003022,"change":-0.8,"floatShares":483945244,"shares":484206716,"eps":9.05521,"lyrEps":8.746592,"pbRate":4.31,"amount":88006166,"amplitude":0.011598,"volumeRatio":0.383987,"dividePrice":4.397397,"prevYearClose":281.58,"fiveDayClose":264.82,"twentyDayClose":270.34},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":483945244,"roa":"6.61%","roe":"14.35%","lyrEps":8.746592,"volumeRatio":0.383987,"shares":484206716,"dividePrice":4.397397,"high":265.3,"amplitude":0.011598,"preClose":264.71,"low":262.23,"week52Low":253.04,"pbRate":"4.31","psRate":"5.25","week52High":311.319,"institutionHeld":0,"latestPrice":263.91,"committee":0.774194,"eps":9.055210515374897,"divideRate":0.016778,"volume":333720,"delay":0,"ttmEps":9.055210515374897,"open":264,"prevYearClose":281.58,"prevWeekClose":260.57,"prevMonthClose":260.57,"prevQuarterClose":281.58,"fiveDayClose":264.82,"twentyDayClose":270.34,"sixtyDayClose":281.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2025-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2025-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-03-11","defaultRemindTime":1741561200000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-09","payableDate":"2025-03-11","currency":"USD","dateTimestamp":1741525200000,"payDate":"2025-04-09"},{"date":"2025-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739228400000,"name":null,"time":"","dateTimestamp":1739192400000,"actualEps":null},{"date":"2024-09-09","symbol":"CSL.AU","amount":1.45,"announcedDate":"2024-08-13","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-10","defaultRemindTime":1725840000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-02","payableDate":"2024-09-10","currency":"USD","dateTimestamp":1725804000000,"payDate":"2024-10-02"},{"date":"2024-08-13","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723507200000,"name":null,"time":"","dateTimestamp":1723471200000,"actualEps":null},{"date":"2024-03-11","symbol":"CSL.AU","amount":1.19,"announcedDate":"2024-02-13","type":"dividend","market":"AU","newRecordDate":"2024-03-12","defaultRemindTime":1710111600000,"name":"CSL 公司","recordDate":"2024-04-03","payableDate":"2024-03-12","currency":"USD","dateTimestamp":1710075600000,"payDate":"2024-04-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512972131","title":"CSL’s mixed half-year: plasma strength offsets vaccine weakness, bright outlook maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2512972131","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512972131?lang=en_us&edition=fundamental","pubTime":"2025-02-18 08:42","pubTimestamp":1739839369,"startTime":"0","endTime":"0","summary":"CSL  has posted its half-year results, delivering results that are best described as mixed. At the headline level, revenue climbed around five per cent, while net profit after tax and amortisation  also nudged upward in the low single digits. Beneath these top-line numbers, the company reported a robust rebound in plasma collections, which was offset by weaker sales of its Seqirus influenza vaccines. Despite these mixed signals, management has reaffirmed guidance for FY25, projecting 10-13 per cent NPATA earnings per share  growth and a five to seven per cent lift in revenue.From a valuation perspective, CSL trades on roughly 22× enterprise value/ earnings before interest and taxes  – reasonable, if not cheap, compared to historical averages for a company that has delivered consistent double-digit growth. High barriers to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/csl-s-mixed-half-year-plasma-strength-offsets-vaccine-weakness-bright-outlook-maintained","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/csl-s-mixed-half-year-plasma-strength-offsets-vaccine-weakness-bright-outlook-maintained","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0728928796.USD","BK7511","BK7508","BK7067","LU1169590202.USD","BK4086","BK7501","CSL","SG9999004303.SGD","LU1169589451.USD","CSL.AU","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2512979589","title":"Should you buy the dip on ASX healthcare stocks CSL, Cochlear and Pro Medicus?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512979589","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512979589?lang=en_us&edition=fundamental","pubTime":"2025-02-18 05:00","pubTimestamp":1739826009,"startTime":"0","endTime":"0","summary":"In this article, we’ll investigate the best and worst bits of the recent first-half financial year 2025 results  releases of three of the ASX’s premier healthcare companies, CSL Limited , Cochlear , and Pro Medicus .We’ll also check out the market’s response to the results, including the dip in each of their share prices, as well as all the changes in major brokers’ ratings and target prices. Do the experts think you should buy the dip on these blue-chip ASX healthcare stocks?CSL is a true Australian success story, having grown from humble beginnings as Commonwealth Serum Laboratories founded in 1916, to a globally significant healthcare company. It operates across the world with divisions including CSL Behring , CSL Seqirus , and CSL Vifor .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/should-you-buy-the-dip-on-asx-healthcare-stocks-csl-cochlear-and-pro-medicus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/should-you-buy-the-dip-on-asx-healthcare-stocks-csl-cochlear-and-pro-medicus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU1868836591.USD","BK4550","BK7094","IE00B19Z3B42.SGD","BK4585","BK4516","CSL.AU","LU0728928796.USD","LU2471134879.HKD","LU2237443549.SGD","LU2237443382.USD","SGXZ23171101.USD","LU0106261612.USD","LU1868836914.USD","BK4552","LU1868837300.USD","LU2237443978.SGD","LU2750360641.GBP","XKO.AU","LU0205194284.USD","LU2237438978.USD","BK7508","HAE","COH.AU","IE0004086264.USD","LU1868836757.USD","LU2237443465.HKD","CSL","XAO.AU","LU0012050646.USD","XJO.AU","IE00B19Z3581.USD","BK4504","LU0061475181.USD","PME.AU","BK7067","LU1668664300.SGD","LU1791807156.HKD","LU1868837136.USD","LU0106831901.USD","LU2471134796.USD","LU2471134523.USD","IE00B64QTZ34.USD","LU2471134952.CNY","LU1169589451.USD","BK4086","LU0205193047.USD","SG9999004303.SGD","BK4127","BK7501"],"gpt_icon":0},{"id":"2511981101","title":"CSL First Half 2025 Earnings: EPS Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2511981101","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511981101?lang=en_us&edition=fundamental","pubTime":"2025-02-16 06:45","pubTimestamp":1739659541,"startTime":"0","endTime":"0","summary":"CSL ( ASX:CSL ) First Half 2025 Results Key Financial Results Revenue: US$8.48b (up 5.3% from 1H 2024). Net income...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-first-half-2025-earnings-eps-misses-expectations","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL","CSL.AU"],"gpt_icon":0},{"id":"2511028036","title":"Top brokers name 3 ASX shares to buy next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2511028036","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511028036?lang=en_us&edition=fundamental","pubTime":"2025-02-16 04:15","pubTimestamp":1739650500,"startTime":"0","endTime":"0","summary":"It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Her","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/16/top-brokers-name-3-asx-shares-to-buy-next-week-16-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0971096721.USD","LU0061475181.USD","BK7501","LU1868837136.USD","LU2089284900.SGD","CSL.AU","DMP.AU","LU2023251221.USD","BK4585","LU2237443549.SGD","LU0158827781.USD","LU2471134796.USD","LU0096364046.USD","LU1720051108.HKD","IE00BKVL7J92.USD","LU0795875086.SGD","BK4550","LU2347655156.SGD","LU1732800096.USD","LU0795875169.SGD","IE0004086264.USD","LU1868836914.USD","BK4516","LU0320765646.SGD","LU1668664300.SGD","LU2111349929.HKD","LU1868836591.USD","BK4552","BK7067","LU1162221912.USD","LU0098860793.USD","LU1868836757.USD","IE0004091025.USD","BK4588","LU2237443465.HKD","LU0225283273.USD","LU2271345857.HKD","LU2237443978.SGD","PME.AU","IE0034235188.USD","LU2357305700.SGD","LU1989772840.SGD","IE0002270589.USD","BK4581","LU2028103732.USD","LU0912757837.SGD","LU2750360997.AUD","BK7511","IE00BZ1G4Q59.USD","BK7137"],"gpt_icon":1},{"id":"2511641338","title":"Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511641338","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511641338?lang=en_us&edition=fundamental","pubTime":"2025-02-15 07:48","pubTimestamp":1739576911,"startTime":"0","endTime":"0","summary":"CSL Limited  shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257 in the week after its latest half-year results. Revenues of US$8.5b were in line with forecasts, although statutory earnings per share  came in below expectations at US$4.13, missing estimates by 4.4%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for CSL. On the plus side, there w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-analysts-forecasting-csl-limited-234831917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0728928796.USD","BK7511","BK7508","BK7067","LU1169590202.USD","BK4086","BK7501","CSL","SG9999004303.SGD","LU1169589451.USD","CSL.AU","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2511649874","title":"These ASX 200 shares could rise 20% to 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511649874","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511649874?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:34","pubTimestamp":1739568840,"startTime":"0","endTime":"0","summary":"If you are on the lookout for some big returns in 2025, then it could pay to listen to what analysts are saying about the ASX 200 shares in this article. That's because they have been named as buys an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/15/these-asx-200-shares-could-rise-20-to-40-4/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4552","BK4533","BK7067","LU2471134879.HKD","DYL.AU","BK7501","IE00BFXG1179.USD","LU1668664300.SGD","BK4588","LU0106831901.USD","LU2750360997.AUD","LU2237443622.USD","LU2237443895.HKD","CSL.AU","BK7511","LU2237443978.SGD","IE00B19Z3B42.SGD","LU2471134796.USD","LU2471134952.CNY","BK4585","BK7097","IE0034235188.USD","LU1791807156.HKD","BK4550","BK4127","LU2471134523.USD","BK4504","TWE.AU","LU2237443465.HKD","IE0004091025.USD","LU2237443382.USD","BK7083","IE0002270589.USD","LU2750360641.GBP","BK7508","IE00B19Z3581.USD","IE0004086264.USD","LU2237438978.USD","BK7505","IE00BSNM7G36.USD","LU2237443549.SGD","BK4516"],"gpt_icon":0},{"id":"2511660068","title":"European Commission Approves CSL and Arcturus Therapeutics' Kostaive®, the First Self-Amplifying Mrna Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2511660068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511660068?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:30","pubTimestamp":1739539804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA2RQQ7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARCT","BK7501","BK7508","BK4139","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2511667960","title":"European Commission Approves CSL and Arcturus Therapeutics’ Kostaive®, the First Self-Amplifying Mrna Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2511667960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511667960?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:00","pubTimestamp":1739538001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA9KMGMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7508","BK7067","CSL.AU","BK7511","ARCT","BK7501"],"gpt_icon":0},{"id":"2511354951","title":"BRIEF-European Commission Approves CSL's ANDEMBRY (Garadacimab) For The Prevention Of Recurrent Attacks Of Hereditary Angioedema (HAE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2511354951","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511354951?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:05","pubTimestamp":1739448311,"startTime":"0","endTime":"0","summary":"BRIEF-European Commission Approves CSL's ANDEMBRY (Garadacimab) For The Prevention Of Recurrent Attacks Of Hereditary Angioedema (HAE)Feb 13 (Reuters) - CSL Ltd CSL.AX:EUROPEAN COMMISSION APPROVES CSL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUAWJDZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7508","BK7511","BK7067"],"gpt_icon":0},{"id":"2511954607","title":"European Commission Approves CSL's Andembry® (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (Hae)","url":"https://stock-news.laohu8.com/highlight/detail?id=2511954607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511954607?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUAWJDZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","CSL.AU","BK7067","BK7508","BK7501"],"gpt_icon":0},{"id":"2511585104","title":"BMRN vs. CSLLY: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511585104","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511585104?lang=en_us&edition=fundamental","pubTime":"2025-02-13 00:40","pubTimestamp":1739378412,"startTime":"0","endTime":"0","summary":"Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical  and CSL Limited Sponsored ADR . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.Currently, BioMarin Pharmaceutical has a Zacks Rank of #2 , while CSL Limited Sponsored ADR has a Zacks Rank of #5 . This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that BMRN is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.BioMarin Pharma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmrn-vs-cslly-stock-better-164012184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSL.AU","BK4566","BMRN","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","BK4139","IE00B19Z3581.USD","CSLLY"],"gpt_icon":0},{"id":"2510534586","title":"3 ASX growth stocks to watch as earnings hit a turning point","url":"https://stock-news.laohu8.com/highlight/detail?id=2510534586","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510534586?lang=en_us&edition=fundamental","pubTime":"2025-02-12 14:02","pubTimestamp":1739340159,"startTime":"0","endTime":"0","summary":"This interview was recorded on Tuesday 11 February 2025.Share markets are at near-highs. The RBA is expected to start cuts next week. There’s change in the air and something that seems like…hope. FNArena’s Rudi Filapek-Vandycknotes that all reporting seasons have their own character and this one spells a significant change compared to the more depressed mood of August 2024. The optimism is back and Filapek-Vandyck points to a few key reasons.“There is a growing confidence now that earnings in Australia have bottomed, and we will see better times ahead. That’s already being reflected in forecasts,” he says.He adds that the prospect of rate cuts supports his optimism and his view that 2025 may be the year that the “60% that haven’t performed over the past two years” finally get going.The two sectors and three stocks to watch this season. “The one telecommunication company that has been put forward as potentially shooting out the lights this year is Superloop and they have been on a tear ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/3-asx-growth-stocks-to-watch-as-earnings-hit-a-turning-point","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/3-asx-growth-stocks-to-watch-as-earnings-hit-a-turning-point","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7124","BK7016","TLX.AU","ACL.AU","HLS.AU","BK7067","BK7094","BK7042","CSL.AU","BK7501","BK7015","WTC.AU","CBA.AU","COH.AU","TPG.AU","XAO.AU","BK7054","TLS.AU","INTEU","RHC.AU","BK7046","BK7511","BK7007","BK7508","BK7135","BK7509","XJO.AU","XKO.AU","IDX.AU","SHL.AU","SLC.AU","RMD.AU","BK7503","PME.AU","BK7113","HUB.AU","MQG.AU"],"gpt_icon":0},{"id":"2510348591","title":"4 ASX 300 shares with ex-dividend dates before this week ends","url":"https://stock-news.laohu8.com/highlight/detail?id=2510348591","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510348591?lang=en_us&edition=fundamental","pubTime":"2025-02-12 12:33","pubTimestamp":1739334783,"startTime":"0","endTime":"0","summary":"Earnings season is accelerating this week, as we hear from ASX 300 shares like Commonwealth Bank of Australia (ASX: CBA), Computershare Ltd (ASX: CPU), and CSL Ltd (ASX: CSL). While all eyes will be o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/12/4-asx-300-shares-with-ex-dividend-dates-before-this-week-ends/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7033","ANN.AU","BK7501","BK7510","CBA.AU","BK7007","REIT","BK7503","BK7135","BK7005","BK7508","RMD.AU","DDR.AU","SCG.AU","BK7511","BK7162","CPU.AU","CSL.AU","BK7067","BK7068","BK7126","BK7157","REIT.AU"],"gpt_icon":0},{"id":"2510157423","title":"Top brokers name 3 ASX shares to buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2510157423","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510157423?lang=en_us&edition=fundamental","pubTime":"2025-02-12 10:50","pubTimestamp":1739328625,"startTime":"0","endTime":"0","summary":"Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:. Analysts at Goldman Sachs have reaffirmed their buy rating on this biotechnology giant's shares with a trimmed price target of $318.40. According to the note, the broker felt that CSL delivered a mixed half year result this week. It notes that its strong immunoglobulin growth and solid gross margin improvements in the CSL Behring business was overshadowed by weakness across its Seqirus influenza vaccines segment. However, given the importance of the CSL Behring business, the broker believes investors should be focusing on its improvements and is confident that the company will deliver on its annual double-digit earnings growth target over the medium term. The CSL share price ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/12/top-brokers-name-3-asx-shares-to-buy-today-12-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7507","BK7067","BK7501","BHP.AU","BK7095","BRG.AU","BK7508","BK7511","BK7119","CSL.AU"],"gpt_icon":0},{"id":"2510365073","title":"Flu Vaccines Proving Problematic for CSL -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2510365073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510365073?lang=en_us&edition=fundamental","pubTime":"2025-02-12 06:30","pubTimestamp":1739313000,"startTime":"0","endTime":"0","summary":"2230 GMT - CSL's vaccines business is in need of a shot in the arm. UBS says CSL's Seqirus unit missed its 1H revenue forecast by 6% as U.S. demand weakened again. Analyst Laura Sutcliffe thinks elevated flu cases in FY 2025 will drive a recovery in immunization rates the following year, but probably not back to FY 2024 levels. \"In general, margins tend to scale with sales in vaccines,\" UBS says. Government contracts for H5  pandemic readiness are a bright spot. UBS estimates revenue from these contracts at US$150 million in 2H, building on an estimated in US$60 million in 1H. Still, UBS believes the percentage drop in FY 2025 vaccine sales will be in the mid-to-high teens when these contracts are excluded. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0728928796.USD","BK7511","BK7508","BK7067","LU1169590202.USD","BK4086","BK7501","CSL","SG9999004303.SGD","LU1169589451.USD","CSL.AU","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2510365984","title":"Everything you need to know about the latest CSL dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2510365984","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510365984?lang=en_us&edition=fundamental","pubTime":"2025-02-12 06:15","pubTimestamp":1739312143,"startTime":"0","endTime":"0","summary":"Yesterday, we got one of the first earnings reports of the season from a major blue chip share. That blue chip share was healthcare stock CSL Ltd (ASX: CSL). We discussed all of the major details at t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/12/everything-you-need-to-know-about-the-latest-csl-dividend-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1169590202.USD","BK4086","BK7067","BK7501","CSL.AU","LU1169589451.USD","BK7508","SG9999004303.SGD","BK7511","CSL","LU0728928796.USD","SGXZ23171101.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":2,"totalSize":200}]}}